olivLaw · US equity research
PACS Group, Inc. PACS
Services-Skilled Nursing Care Facilities · SIC 8051 · Vertical: Health services (SIC 805x)
PACS Group is one of the largest post-acute healthcare platforms in the United States, operating skilled nursing facilities through a 'locally led, centrally supported' model. In an industry where demand grows with an aging population, the company reported total revenue of 5.3 billion USD in 2025 and raised its 2026 Adjusted EBITDA guidance.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, PACS Group, Inc. (PACS) stock was 50.26 USD (+7.67% on the day), with market capitalisation 8.0 bn USD, P/E 28.0 on diluted EPS of 1.80 USD over the last 12 months, dividend yield 0.43%, beta 0.63, 52-week range 10.58–50.26 USD. Latest reported quarter (Q3 2026): revenue of 1.5 bn USD (+11.5% YoY), net income of 60.8 m USD (+16.1% YoY), diluted EPS 0.37 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 62.7
- strong (55–70)
- Bollinger (20, 2)
- 42.98 – 50.67
- in the upper half of the band · %B 0.95 · band width 16.4%
- SMA 50 / 200
- 44.39 / 39.86
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 1.23 / 1.20
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +17.7% | −1.1% | +18.8 pp | — |
| 3 months | +10.1% | −0.5% | +10.6 pp | — |
| 6 months | +48.6% | +4.4% | +44.2 pp | — |
| Year to date | +30.9% | +12.3% | +18.6 pp | — |
| 1 year | +303.4% | +13.5% | +289.8 pp | +14.2% |
| 3 years | unavailable | +76.4% | unavailable | +173.3% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.4 bn | 1.4 bn | 1.4 bn | 1.5 bn |
| Cost of revenue | 949.4 m | 1.0 bn | 1.0 bn | 1.0 bn | 1.0 bn | 1.1 bn | 1.1 bn | 1.1 bn |
| Operating income | 72.0 m | 48.1 m | 80.5 m | 86.3 m | 94.7 m | 120.0 m | 109.3 m | 99.7 m |
| Interest expense | 9.3 m | 6.9 m | 4.4 m | 8.5 m | 8.6 m | 6.4 m | 6.0 m | 5.1 m |
| Pre-tax income | 61.2 m | 42.7 m | 78.6 m | 76.3 m | 86.8 m | 113.7 m | 105.8 m | 91.3 m |
| Income tax | 25.0 m | 14.4 m | 27.6 m | 24.0 m | 27.0 m | 33.1 m | 29.5 m | 30.5 m |
| Net income | 37.2 m | 28.5 m | 51.0 m | 52.4 m | 59.7 m | 80.7 m | 76.4 m | 60.8 m |
| Diluted EPS | 0.24 ≈ | 0.17 | 0.31 | 0.32 | 0.46 ≈ | 0.50 | 0.47 | 0.37 |
| Operating cash flow | 64.6 m | 150.2 m | 52.6 m ≈ | 204.8 m ≈ | -3.4 m | 236.3 m | 135.5 m ≈ | 211.2 m ≈ |
| Dividends paid | 0 | 0 | 0 ≈ | 0 ≈ | 0 | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 50 percentile of its own 10-quarter history (min 13.2, median 27.5, max 94.0; quarters with earnings only).
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 2.4 bn | 3.1 bn | 4.1 bn | 5.3 bn |
| Revenue YoY | unavailable | +28.5% | +31.4% | +29.3% |
| Net income | 150.5 m | 112.9 m | 55.8 m | 191.5 m |
| Net income YoY | unavailable | −25.0% | −50.6% | +243.5% |
| Diluted EPS | 1.17 | 0.88 | 0.38 | 1.22 |
| Diluted EPS YoY | unavailable | −24.8% | −56.8% | +221.1% |
| net % | 6.2% | 3.6% | 1.4% | 3.6% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 197.0 m USD
- Financial debt
- 249.3 m USD
- Net debt
- 52.3 m USD
- Equity
- 952.4 m USD
- Total assets
- 5.6 bn USD
- Debt / equity
- 0.26x
- Current ratio
- 1.07x
- ROE
- 23.0%
- ROA
- 3.5%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 2.4 bn | 3.1 bn | 4.1 bn | 5.3 bn | SEC (XBRL)· 27 Feb 2026verified |
| Cost of revenue | 1.9 bn | 2.4 bn | 3.3 bn | 4.1 bn | SEC (XBRL)· 27 Feb 2026verified |
| Gross profit | 560.7 m ≈ | 663.8 m ≈ | 792.6 m ≈ | 1.2 bn ≈ | SEC (XBRL)· 27 Feb 2026derived |
| Operating income | 229.4 m | 207.8 m | 123.1 m | 309.6 m | SEC (XBRL)· 27 Feb 2026verified |
| Interest expense | 25.5 m | 49.9 m | 44.3 m | 28.4 m | SEC (XBRL)· 27 Feb 2026verified |
| Pre-tax income | 207.0 m | 157.3 m | 101.6 m | 284.5 m | SEC (XBRL)· 27 Feb 2026verified |
| Income tax | 56.5 m | 44.4 m | 46.2 m | 93.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Net income | 150.5 m | 112.9 m | 55.8 m | 191.5 m | SEC (XBRL)· 27 Feb 2026verified |
| Diluted EPS | 1.17 | 0.88 | 0.38 | 1.22 | SEC (XBRL)· 27 Feb 2026verified |
| Weighted average diluted shares | 128.7 m | 128.7 m | 148.6 m | 156.7 m | SEC (XBRL)· 27 Feb 2026verified |
| Dividend per share | 0.47 | 0.62 | 0.22 | — | SEC (XBRL)· 19 Nov 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 58.3 m | 73.4 m | 157.7 m | 197.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Receivables | — | 547.8 m | 641.8 m | 628.1 m | SEC (XBRL)· 27 Feb 2026verified |
| Current assets | — | 722.1 m | 938.3 m | 1.1 bn | SEC (XBRL)· 27 Feb 2026verified |
| Goodwill | 55.2 m | 59.0 m | 60.8 m | 61.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Total assets | — | 3.5 bn | 5.2 bn | 5.6 bn | SEC (XBRL)· 27 Feb 2026verified |
| Accounts payable | — | 140.9 m | 175.1 m | 192.2 m | SEC (XBRL)· 27 Feb 2026verified |
| Short-term debt | — | 16.8 m | 14.9 m | 4.5 m | SEC (XBRL)· 27 Feb 2026verified |
| Long-term debt | — | 195.7 m | 251.0 m | 244.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Current liabilities | — | 456.9 m | 978.4 m | 1.0 bn | SEC (XBRL)· 27 Feb 2026verified |
| Total liabilities | — | 3.4 bn | 4.5 bn | 4.6 bn | SEC (XBRL)· 27 Feb 2026verified |
| Equity | 68.7 m | 101.7 m | 715.7 m | 952.4 m | SEC (XBRL)· 27 Feb 2026verified |
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | 92.6 m | 63.7 m | 367.3 m | 404.2 m | SEC (XBRL)· 27 Feb 2026verified |
| Investing cash flow | -75.3 m | -172.8 m | -442.7 m | -264.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Financing cash flow | 12.4 m | 129.6 m | 117.5 m | -69.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Dividends paid | 60.3 m | 80.4 m | 33.7 m | 0 | SEC (XBRL)· 27 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 48 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 8.0 bn USD
Key indicators
Coverage and freshness
Score by group
- Balance sheet60
- Valuation9
- Quality78
- Growth55
- Returns0
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 2.86 – 46.66 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E37.52 – 46.66 (Mid 42.94)3 companies used · median multiple 23.9x · quartiles 20.9x – 26.0xENSG, HCSG, NHC
- Dividend discount (DDM)2.86 – 3.84 (Mid 3.28)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 48/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 27.5% | 100 (on a fixed band) | 17% |
| Net margin · Quality | 4.9% | 40 (vs peers) | 10% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 29.7% | 100 (on a fixed band) | 14% |
| EPS CAGR 3Y · Growth | 1.4% | 9 (on a fixed band) | 14% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 16.2x | 100 (on a fixed band) | 10% |
| Current ratio · Balance sheet | 0.8x | 0 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | 28.0x | 9 (on a fixed band) | 17% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | 0.0% | 0 (on a fixed band) | 10% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet60/100 · 2/3 factors with a value
- Growth55/100 · 2/2 factors with a value
- Quality78/100 · 2/3 factors with a value
- Returns· partial0/100 · 1/2 factors with a value
- Valuation· partial9/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
PACS Group, Inc. (PACS). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 5.3 bn USD in 2025; YoY growth 29.3%; net margin 4.9%; ROE 26.6%.
The estimated value range is 20.19–25.25 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 23.11 USD, the price of 50.26 USD leaves a potential of -54.0% (value / price − 1) and a margin of safety of -117.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 48/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns, valuation. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 27.5%
- Revenue CAGR 3Y: 29.7%
- Interest coverage: 16.2x
What contradicts it
- EPS CAGR 3Y: 1.4%
- Current ratio: 0.8x
- P/E (TTM): 28.0x
- Shareholder yield (distributions): 0.0%
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Net debt / EBITDA, EV/EBITDA, FCF yield, Payout ratio (FCF).
Versus the vertical median
Health services (SIC 805x) · same industry group (3-digit SIC) · compared with 5 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ENSGEnsign Group, Inc | 11.0 bn | 28.0 | 17.1% | 7.0% | +18.7% | +1% / +76% |
| PACSPACS Group, Inc. | 8.0 bn | 28.0 | 26.6% | 4.9% | +29.3% | +303% / unavailable |
| NHCNational Healthcare Corp | 3.3 bn | 23.9 | 13.1% | 9.0% | +16.1% | +56% / +177% |
| BKDBrookdale Senior Living Inc. | 2.7 bn | — | -362.1% | -4.5% | +2.2% | +1% / +111% |
| HCSGHealthcare Services Group, Inc. | 1.8 bn | 17.9 | 20.4% | 5.6% | +7.1% | +41% / +173% |
| SNDASonida Senior Living, Inc. | 1.8 bn | — | -26.7% | -23.3% | +25.2% | +14% / +282% |
1- and 3-year price returns: for PACS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 31.96 Total return -36% · Per year -36% | 56.25 Total return 12% · Per year 12% | 84.37 Total return 68% · Per year 68% |
| 3 years | 37.91 Total return -25% · Per year -9% | 74.39 Total return 48% · Per year 14% | 121.49 Total return 142% · Per year 34% |
| 5 years | 44.97 Total return -11% · Per year -2% | 98.38 Total return 96% · Per year 14% | 174.95 Total return 248% · Per year 28% |
- Exit P/E± 18.60
- Net margin± 13.02
- Annual revenue growth± 9.71
- Annual dilution± 1.09
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 04 Aug 2026; since then the company filed 8-K (03 Nov 2026 · results), 10-Q (03 Nov 2026).
In brief
PACS Group is one of the largest post-acute healthcare platforms in the United States, operating skilled nursing facilities through a 'locally led, centrally supported' model. In an industry where demand grows with an aging population, the company reported total revenue of 5.3 billion USD in 2025 1 and raised its 2026 Adjusted EBITDA guidance 3.
SWOT
Strengths
Weaknesses
- High dependence on Medicare and Medicaid payments, with margins sensitive to reimbursement changes 1.
- Reported material weaknesses in internal control, including over the revenue process and risk assessment 1.
- Newer facilities have lower occupancy and quality ratings than mature ones, delaying their contribution to profitability 2.
Opportunities
- Integrating the Eduro facilities and other acquisitions could expand geographic reach and scale 3.
- Consolidation of a fragmented market could offer acquisition opportunities from sellers under financial pressure 2.
- Growing demand for post-acute care could support occupancy and a higher-acuity patient mix 1.
Threats
- Changes to federal Medicaid policy and minimum staffing rules could reduce revenue or raise costs 1.
- Shortages of qualified staff and wage pressure from other industries could limit operating capacity 1.
- Competition from other operators for the same facilities and patients could erode acquisition returns 2.
Risks
- Dependence on public reimbursementhigh
Revenue relies on Medicare and Medicaid payments, and any rate cut or shift in patient mix could affect results 1.
- Internal control weaknesseshigh
The company reported material weaknesses over revenue controls and risk assessment, which could affect confidence in the financial statements 1.
- Staffing shortagesmedium
Higher labor costs and minimum staffing requirements could raise expenses and limit admissions 1.
- Acquisition integration riskmedium
Rapidly integrating many facilities, including those from Eduro, could strain local teams and central systems 3.
- Regulation and approvalslow
Certificate of need and licensing requirements could delay or block expansion, and regulatory changes could alter competitive conditions 1.
Investment thesis
What would need to be true (bull case)
- Structural demand for post-acute care, combined with a fragmented market, could allow continued growth through acquisitions if integration stays effective 23.
- High quality ratings and occupancy at mature facilities suggest the operating model could be replicated in recently acquired facilities 12.
- The raised 2026 Adjusted EBITDA guidance points to operating momentum that could continue into the second half of the year 3.
What would break the thesis
- Dependence on government programs means margins could be hit quickly by legislative changes or rate reductions 1.
- Reported internal control problems could draw regulatory attention and slow reporting processes 1.
- Large acquisitions may bring debt and operational complexity, and integration is not always quick, which could reduce returns 13.
What to watch
- Closing of the remaining 14 Eduro facilities and their operational integrationQ3-Q4 2026
- Remediation of the material weaknesses in internal control reported for 2025next 10-K
- Occupancy and skilled mix trends in the ramping facility cohortQ3 2026
- Changes to federal minimum staffing rules and Medicaid reimbursement2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 04 Aug 2026; since then the company filed 8-K (03 Nov 2026 · results), 10-Q (03 Nov 2026).
The business
PACS Group, Inc. is a post-acute healthcare company focused on skilled nursing care through a portfolio of independently operated facilities, supported by PACS Services 1. Historically it grew by acquiring underperforming custodial care facilities and converting them into higher-acuity short-term transitional care facilities. As of June 30, 2026, the portfolio comprised 324 facilities across 17 states 2.
The operating model combines local administrator autonomy with centralized technology and back-office support, including a real-time operational data platform, an electronic health record system and compliance support 1. Quality is tracked through the QM Star rating and occupancy, and acquired facilities typically undergo a transition period of up to three years 1.
Revenue depends largely on third-party payors, especially Medicare and Medicaid, making payor mix and reimbursement rates central to results 1. In 2026 the company agreed to acquire the operations of 34 facilities from Eduro Healthcare, and 20 Texas facilities closed on August 1, 2026 3.
Segments
Market context
Trends
- Growing demand for skilled caretailwind
An aging population and rising chronic conditions support demand for SNFs, which remain the lowest-cost facility-based post-acute care 2. If this trend continues, it could support occupancy.
- Industry consolidationtailwind
Many small and independent operators face billing, staffing and funding pressures, which may lead them to sell facilities 2. This creates acquisition opportunities for larger operators.
- Staffing pressureheadwind
Shortages of qualified staff and minimum staffing rules can raise labor costs and restrict admissions 1. If reimbursement does not rise enough, margins could be affected.
- Reimbursement and public policymixed
Medicare and Medicaid reimbursement has risen steadily in recent years, but legislative changes and cost-containment initiatives could limit payments 12. The net effect depends on federal and state policy.
Competitive position
The market is fragmented, with many small and independent operators alongside a limited number of large platforms, so PACS competes with both national groups and local operators 2. Its competitive position rests on scale, the centralized support model and quality performance measured by the QM Star rating 1.
Competition for qualified staff also involves employers outside healthcare, which raises recruitment costs 1. The company differentiates through training programs for administrators and clinicians and pay packages linked to operating performance 1.
- Small and independent SNF operators
Make up most of the roughly 5,000 operators with fewer than 100 facilities, especially in rural areas 2.
- Ten largest SNF platforms
Groups with more than 100 facilities that together hold about a tenth of US SNFs 2.
- Other post-acute care providers
Rehabilitation and other care settings competing for the same patients discharged from hospitals 1.
- Operators divesting facilities
Sellers that act as acquisition sources for PACS and also compete for the same assets 2.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- PACs , campaigns spent $3 billion on ads . What were the most misleading messages to voters ? – PolitiFactSurge — GDELT DOC · 04 Nov 2026 · RO
- Inside the Secretive, Contradictory World of Campaign Ads Funded by AI Super PACsBellingcat · 02 Nov 2026 · EN
- ‘Pop-up’ super PACs pour $637 million into 2026 midterm racesCNBC — Top News · 31 Oct 2026 · EN
- Scoop: Dems quietly guide super PACs to boost spoiler House candidatesAxios · 21 Oct 2026 · EN
- Trump-aligned super PACs pour millions into once-safe GOP House seatsCNBC — Top News · 21 Oct 2026 · EN
- Building cloud-native PACS on AWSAWS Architecture Blog · 17 Sept 2026 · EN
- PACS Group Shares Rise 3.3% as Company Plans Florida Expansion and Completes More Eduro AcquisitionsYahoo Finance — News · 02 Sept 2026 · EN
- Aipac-linked Super Pacs spend millions in California to thwart progressive candidateThe Guardian World · 06 Aug 2026 · RO
- Why corporate AI super PACs spent $27 million on a local electionThe Verge · 23 Jun 2026 · EN
- Republican-linked PACs funding Democratic US primaries: Why it mattersAl Jazeera English · 23 Jun 2026 · EN
SEC filings
- Quarterly report03 Nov 2026
- Current report03 Nov 2026Results of operations · Financial statements and exhibits
- Current report21 Sept 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report04 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report04 Aug 2026
- Current report15 Jun 2026Shareholder vote
- Current report11 May 2026Results of operations · Financial statements and exhibits
- Quarterly report11 May 2026
- Proxy statement28 Apr 2026
- Current report27 Apr 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / PACS Group, Inc. · 27 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / PACS Group, Inc. · 04 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / PACS Group, Inc. · 04 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.